Amgen Cholesterol Drug Wins U.S. Approval for Some Patients

  • Repatha can be prescribed when statins and diet aren't enough
  • Drug will cost $14,100 a year, about the same as competitor

Amgen Inc. won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.